messag gilead held first earn call new ceo daniel day
helm earli tenur focus evalu research organ
pipelin strategi thu far appear larg unchang mr day
conduct broader strateg review discuss long-term
strategi vision later year commerci continu encourag
hiv platform includ taf launch growth prep financi gilead revisit
guidanc adjust selonsertib filgotinib call reduc
pt remov selonsertib estim
result report revenu versu our/street estim
non-gaap ep vs our/street estim product
side key beat driven biktarvi vs consensu epclusa
vs consensu end year cash equival
model chang updat model reflect result chang includ
increas biktarvi sale increas po filgotinib
remov selonsertib estim
nash atla combin studi top-lin data expect
determin go-forward combin
hiv file snda descovi prep april anticip review time
month approxim oct compani expect phase data earlier
stage candid
inflamm filgotinib compani expect file ema
us compani initi request fda provid updat
discuss potenti file time manta studi remain potenti
rate-limit step file us on-going expect data
sjogren syndrom cutan lupu erythematosu
hematology/oncolog present data mcl
posit intend file approv also plan file ind
allogen prev look forward updat
hbv expect data phase studi
page analyst certif import disclosur
price target previous per share base dcf analysi forecast probability-weight revenu
expens assum discount rate termin growth rate
suscept risk appli entir biotech industri includ develop regulatori commerci manufactur
financ ip risk specif includ
commerci risk possibl may fail introduc new product market current product could produc less revenu
expect patient identif may slower expect product may receiv unfavor payor reimburs
clinic risk sever key pipelin product still clinic develop may delay clinic trial initi enrol
unexpect safeti issu efficaci lower expect
regulatori risk clinic trial ultim success possibl gild medicin approv global regulatori
agenc agenc may requir addit long-term data could delay potenti approv
ip risk depend intellectu properti protect control trade secret technolog innov inabl
defend patent could result increas gener competit addit compani may accus infring ip
current sever legal proceed relat product
competitor risk hiv hcv busi repres signific amount total product sale mix could face increas
competit aggress competit face signific competit therapi develop includ liver diseas
inflamm oncolog multipl compani develop therapi could prove better safeti efficaci
move faster market
page analyst certif import disclosur
mm except per share data
royalti contract revenu
factset consensu
total incom expens net
incom tax
net loss attribut non-controlling interest
net incom attribut
cog
sg
tax
non-gaap net incom attribut
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
